FP
ANIP icon

Foundry Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Foundry Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-69,270
Closed -$2.82M – 386
2020
Q1 		$2.82M Buy
+69,270
New +$3.68M 0.16% 180

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Foundry Partners's ANIP Position: Q2 2020 in Review

Foundry Partners sold out of ANI Pharmaceuticals (ANIP) in Q2 2020, closing a stake of 69,270 shares — an estimated $2.82M sold.

Foundry Partners first reported a position in ANIP in Q1 2020 and held it in 1 quarter. The position peaked at $2.82M in Q1 2020. 134 funds tracked by Wall St. Rank hold ANIP as of Q2 2020.

  • Foundry Partners reported no remaining ANI Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Foundry Partners sold 69,270 ANI Pharmaceuticals shares in Q2 2020, an estimated $2.82M.
  • Foundry Partners first reported a position in ANI Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Foundry Partners's ANI Pharmaceuticals position peaked at $2.82M in Q1 2020.
  • 134 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2020.

Based on Foundry Partners's 13F filing for Q2 2020, filed 3 Aug 2020.